A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV-Reference-Cited by-同舟云学术

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV

Published:2021-01-25 Issue:2 Volume:10 Page:161-172
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Bukkems Vera E.¹,Post Teun M.²,Colbers Angela P.¹,Burger David M.¹,Svensson Elin M.¹³

Affiliation:

1. Department of Pharmacy Radboud Institute for Health Sciences (RIHS) Radboud University Medical Center Nijmegen The Netherlands

2. Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P) Leiden The Netherlands

3. Department of Pharmacy Uppsala University Uppsala Sweden

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12586

Reference40 articles.

1. DHHS.Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.https://files.aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.2020. Accessed March 3 2020.

2. Three new residual error models for population PK/PD analyses

3. Pregnancy-Induced Changes in Pharmacokinetics

4. Antiretroviral Pharmacokinetics in Pregnant Women

5. Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between raltegravir trough plasma concentration and virologic response and the impact of therapeutic drug monitoring during pregnancy;International Journal of STD & AIDS;2022-12-18